Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting
Cataldo Patruno(Magna Graecia University), Maddalena Napolitano(University of Molise), Fabrizio Martora(Federico II University Hospital), Anna Belloni Fortina(University of Padua), Barbara Cocuroccia(Istituto Dermopatico dell'Immacolata), Valeria Boccaletti(University of Milan), Giacomo Dal Bello, Elena Pezzolo(Ospedale San Bortolo), Giuseppe Lauletta(University of Naples Federico II), Francesca di Vico(University of Naples Federico II), Filomena Russo(University of Siena), Francesca Caroppo(University of Padua), Mariateresa Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia)
Cited by 15
Related Papers
Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study
|Journal of Investigative Dermatology|2005|644
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients
|Journal of the European Academy of Dermatology and Venereology|2020|248
Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial
|Arthritis & Rheumatism|2011|216
The European baseline series in 10 European Countries, 2005/2006 – Results of the European Surveillance System on Contact Allergies (ESSCA)
|Contact Dermatitis|2009|181
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
|Journal of Allergy and Clinical Immunology|2020|160